Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bico InstantScreen

This article was originally published in The Gray Sheet

Executive Summary

Rapid HIV diagnostic test will be marketed worldwide under an exclusive agreement with the German-American Institute for Applied Biomedical Research (GAIFAR), which manufactures the product. Preliminary data on the 30-minute test show "100% accuracy" in specificity and sensitivity, Bico says. The firm also acquired rights to the InstantConfirm Western-Blot confirmatory HIV rapid test and InstantDifferentiate rapid test for detecting the difference between HIV-1 and HIV-2. Bico plans initially to target overseas markets; GAIFAR will pursue FDA approval "immediately" for sales in the U.S

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel